PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - McAllister, Peter J.
TI  - TARGET
DP  - 2015 Jun 20
TA  - MD Conference Express
PG  - 7--7
VI  - 15
IP  - 9
4099  - http://mdc.sagepub.com/content/15/9/7.1.short
4100  - http://mdc.sagepub.com/content/15/9/7.1.full
AB  - Treatment with AVP-825 significantly reduces headache-associated burden and functional disability. Improvements are seen as early as 45 minutes after treatment, with significant percentages of patients reporting either mild or no disability by 120 minutes postdose. Headache response, improvement in functioning, and reduction in disability corresponded with the rates of patient-reported meaningful relief.